MedTrace Logo

Exploratory Randomized, Controlled, Dose-response Study on the Impact of Nicotine From Five Variants of a Nicotine Tablet (NICOTINE TABLET) on Attention

NCT07408180 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-05

No results posted yet for this study

Summary

This study aims to provide initial insights into the impact of orally delivered nicotine on attentional performance in adult occasional users of nicotine pouches. Nicotine will be administered via a dissolvable tablet for approximately 10 minutes. The main objective of this exploratory study is to characterize the effect of nicotine on attentional performance, using metrics derived from Continuous Performance Test (CPT).

Additionally, a second CPT assessment will be conducted two hours after the first administration to explore the potential sustained effects of nicotine on attention as an exploratory objective.

Conditions

  • Attention

Interventions

OTHER

NICOTINE TABLET-0mg

NICOTINE TABLET (nicotine content 0mg; Mint flavor)

OTHER

NICOTINE TABLET-0.5mg

NICOTINE TABLET (nicotine content 0.5mg; Mint flavor)

OTHER

NICOTINE TABLET-1.0mg

NICOTINE TABLET (nicotine content 1.0mg; Mint flavor)

OTHER

NICOTINE TABLET-1.5mg

NICOTINE TABLET (nicotine content 1.5mg; Mint flavor)

OTHER

NICOTINE TABLET-2.0mg

NICOTINE TABLET (nicotine content 2.0mg; Mint flavor)

Sponsors & Collaborators

  • Philip Morris Products S.A.

    lead INDUSTRY

Principal Investigators

  • Xavier Jaumont, MD · Philip Morris Products S.A.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-28
Primary Completion
2026-03-16
Completion
2026-04-23

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07408180 on ClinicalTrials.gov